Condition
Glycogenesis 2 Acid Maltase Deficiency
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
60%
3 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results75% success
Data Visualizations
Phase Distribution
3Total
P 4 (3)
Trial Status
Completed3
Terminated1
Recruiting1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00567073Recruiting
Pompe Pregnancy Sub-Registry
NCT00701701Phase 4Terminated
Immune Tolerance Induction Study
NCT01288027Phase 4Completed
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
NCT00483379Phase 4Completed
High Dose or High Dose Frequency Study of Alglucosidase Alfa
NCT00731081Completed
Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme®
Showing all 5 trials